STAAR Surgical

STAAR Surgical Co. engages in the development, manufacture, production, marketing, and sale of implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It specializes in refractive and cataract solutions. Its products include intraocular lens and implantable collamer lens. The company was founded in 1982 and is headquartered in Lake Forest, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

STAAR Surgical reports robust Q4 performance and eyes U.S. growth

STAAR Surgical's Q4 2022 earnings call highlighted strong performance, growth opportunities in key markets, and strategic investments for future success. Despite challenges in China, the company remains optimistic about market recovery and growth prospects. With a focus on EVO lens adoption and increased investments, STAAR is well-positioned for continued growth and market expansion.

STAAR Surgical excels in Q1 with strong global sales growth

STAAR Surgical's Q1 2023 earnings call highlighted robust global sales growth, positive market reception, and strategic investments for future expansion. The company aims to strengthen its market position through targeted growth strategies and operational enhancements.

STAAR Surgical reports record Q2 sales, eyes global expansion

STAAR Surgical's Q2 2023 performance showcased record sales and growth, driven by the EVO family of ICLs.
The company's strong presence in APAC, particularly China, and confidence in high-growth outlook are notable.
Challenges include market declines and pricing dynamics, but opportunities lie in global expansion and strategic initiatives.
Balancing growth and profitability remains a focus, with ongoing efforts to enhance market presence and address challenges.

STAAR Surgical reports resilient Q3 performance amidst market challenges

STAAR Surgical's Q3 2023 performance reflects continued growth in ICL sales despite challenges.
The company is navigating macroeconomic headwinds while focusing on market-building initiatives.
Despite a decline in operating income, STAAR remains confident in its growth prospects.
STAAR's strategic focus on new products and market expansion positions it for future success.

STAAR Surgical posts robust Q4 results, eyes global expansion opportunities

STAAR Surgical's strong financial performance and strategic initiatives position the company for continued growth and market leadership.
Challenges from market competition and macroeconomic factors require careful navigation, but opportunities in expanding markets and operational enhancements offer avenues for growth.
With a focus on innovation, profitability, and global expansion, STAAR is poised to capitalize on market trends and drive sustainable growth in the coming years.

STAAR Surgical surpasses Q1 sales targets, eyes global expansion

STAAR Surgical's Q1 2024 performance exceeded expectations, driven by strong global sales growth and strategic milestones. Challenges include addressing discrepancies in sales and unit growth. The company is poised to capitalize on opportunities in China, surgeon training, and international expansion.

STAAR Surgical posts robust Q2 results, eyes global expansion

STAAR Surgical's Q2 2024 performance reflects strong sales growth, improved profitability, and a positive outlook for fiscal 2024.
The company's strategic strengths in global market expansion and innovation position it well for future growth and achieving long-term sales targets.
Challenges in managing operating expenses and sustaining growth rates in key markets require continued strategic focus and operational efficiency.
Opportunities in expanding market presence, driving innovation, and leveraging financial strength present avenues for sustained growth and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

STAAR Surgical Co. engages in the design, development, manufacture, and sale of ophthalmic surgical products. The firm offers implantable lenses for the eye and accessory delivery systems. Its products include refractive and cataract solutions through the Collamer brand. The company was founded in 1982 and is headquartered in Lake Forest, CA.

Bristol-Myers

Darling Ingredients

Funko

Neumora Therapeutics Inc

Occidental Petroleum

Westrock Coffee Holdings LLC

Many investors are familiar with the idea that there are many reasons why insiders sell shares, but there's only one reason they buy. Insider buying indicates a belief that a company's stock is undervalued.

7 Stocks with Strong Insider Buying: December 2023

Citi Trends

Howard Hughes Holdings Inc

Madrigal Pharmaceuticals

Mercury Systems

Impinj

Spectrum Brands Hlds

Some of the biggest insider purchases around and since the Thanksgiving holiday have come from repeat buyers.

See Which Inside Buyers Are Scooping Up More Shares Now

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today announced the appointment of Lilian Zhou to its Board of Directors, effective December 4, 2023. “We welcome Lilian Zhou as a new member to our Board of Directors. Lilian is an accomplished investment portfolio manager who worked at highly regarded Wall Street investment in.

Lilian Zhou Appointed to STAAR Surgical Board of Directors

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today announced that management will participate in the Stephens Annual Investment Conference on Thursday, November 16, 2023. Management will participate in a Fireside Chat on Thursday, November 16, 2023, at 6 a.m. PT / 8 a.m. CT. The Fireside chat will we be webcast live at the.

STAAR Surgical to Present at Stephens Annual Investment Conference (NASH2023)

STAAR Surgical Company (NASDAQ:STAA ) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Brian Moore - Vice President-Investor Relations & Corporate Development Tom Frinzi - President & Chief Executive Officer Patrick Williams - Chief Financial Officer. Conference Call Participants Anthony Petrone - Mizuho Xuyang Li - Jefferies John Young - Canaccord George Sellers - Stephens Margaret Kaczor Andrew - William Blair Steve Lichtman - Oppenheimer Operator Good day ladies and gentlemen.

STAAR Surgical Company (STAA) Q3 2023 Earnings Call Transcript

While the top- and bottom-line numbers for Staar Surgical (STAA) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Here's What Key Metrics Tell Us About Staar Surgical (STAA) Q3 Earnings

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today reported financial results for the third quarter ended September 29, 2023. Third Quarter 2023 Overview Net Sales of $80.3 Million Up 6% Y/Y includes a $0.8 Million sales reduction related to Other Products ICL Sales of $81.1 Million Up 13% Y/Y ICL Units Up 14% Y/Y Gross Ma.

STAAR Surgical Reports Third Quarter 2023 Results

AstraZeneca

Zimmer Biomet Hlds

Baby boomers: Love ‘em or hate ‘em, the juggernaut generation changes every aspect of life it steamrolls through. Now it's doing the same to healthcare.

These healthcare stocks should come to life as boomers live their golden years

STAAR Surgical Company has developed the EVO ICL Lens to treat nearsightedness, offering clear vision without the hassle of contact lenses or glasses. The EVO ICL Lens has gained market share, with the EVO category capturing over 10% of the global market. STAAR's sales and operating profits have been growing steadily, with a net cash position and a valuation of $2.5 billion. However, sales growth is slowing down.

STAAR Surgical: Not In My Sight Yet

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced that it will release financial results for the third quarter ended September 29, 2023 on Wednesday, November 1, 2023 after the market close. STAAR will host a conference call and webcast on Wednesday, November 1 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress. To access th.

STAAR Surgical to Report Third Quarter Results on November 1, 2023

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, is celebrating the 30th anniversary of its proprietary Implantable Collamer® Lens (ICL). The first ICLs were implanted by a group of surgeons in October 1993, including Roberto Zaldivar, MD, Founder of the Zaldivar Institute. The early ICLs have evolved into the current generation of ICLs with a central port – the EVO ICL™ family of lense.

STAAR Surgical Celebrates 30th Anniversary of Implantable Collamer® Lens (ICL)

LAKE FOREST, Calif. , Oct. 10, 2023 /PRNewswire/ -- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, is proud to announce a partnership with renowned actor and comedian, Jimmy O.

Jimmy O. Yang Partners with STAAR Surgical to Shine a Light on Their Vision Correction Lens, EVO ICL

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, will host Vision 2026, the Company's investor day, at the Nasdaq MarketSite in Times Square today. To honor the occasion and celebrate the 40th anniversary of being listed as a public company, Tom Frinzi, Chair of the Board and CEO, along with the company's executive leadership team and STAAR employees, have been invited to ring the Nasda.

STAAR Surgical to Ring Nasdaq Stock Market Closing Bell Following Vision 2026 Investor Day on September 14, 2023

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced that it will host an in-person Investor Day on Thursday, September 14, 2023, beginning at 8:00 a.m. Eastern Time in New York City. The “Vision 2026” Investor Day will highlight key company initiatives and projects including, several next generation product pipeline initiatives, as well as the significant global growth oppo.

STAAR Surgical to Host “Vision 2026” Investor Day on September 14, 2023

Dolby Laboratories

Urstadt Biddle Properties

NEW YORK , Aug. 17, 2023 /PRNewswire/ -- Dolby Laboratories Inc. (NYSE:DLB) will replace Staar Surgical Co. (NASD:STAA) in the S&P MidCap 400 and Staar Surgical will replace Urstadt Biddle Properties Inc. (NYSE:UBA) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, August 22. S&P 500 constituent Regency Centers Corp. (NASD: REG) will acquire Urstadt Biddle Properties in a transaction expected to close soon pending final closing conditions.

Dolby Laboratories Set to Join S&P MidCap 400; Staar Surgical to Join S&P SmallCap 600

STAAR Surgical Company's Q2 FY'23 earnings missed consensus estimates. The key revenue driver for STAA is its Implantable Collamer Lenses, which saw a 21% YoY increase in unit volumes. Despite potential topline growth, the economic realities and valuation multiples suggest STAA is a hold in my opinion.

STAAR Surgical: Economic Realities Beginning To Surface, Reiterate Hold

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced that management will participate in several upcoming investor conferences. STAAR management will participate in the following investor conferences: Canaccord Genuity Annual Growth Conference, Wednesday, August 9. Management Presentation and Q&A at 10:00 a.m. Eastern / 7:00 a.m. Pacific at the following link: https://ws.

STAAR Surgical to Participate in Upcoming Investor Conferences

PlayAGS

Luminar Technologies

Growth stocks are on a tear this year, and while some names will inevitably cool off in the coming weeks, opportunities will always exist. In my opinion, investors should start taking profits from growth stocks trading above their intrinsic value, reinvesting into high-growth companies that trade with a large margin of safety.

3 ‘Strong Buy' Growth Stocks You Should Be Loading Up On Now

STAAR Surgical beat on earnings but missed on revenue for the second quarter. The implantable lens leader also lowered its full-year revenue guidance amid slower-than-expected growth in the U.S. and broader macro concerns.

Why STAAR Surgical Stock Dropped Today

STAAR Surgical Company (NASDAQ:STAA ) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ET Company Participants Brian Moore - Investor Relations Tom Frinzi - President and Chief Executive Officer Patrick Williams - Chief Financial Officer Conference Call Participants Anthony Petrone - Mizuho Group Margaret Kaczor - William Blair Young Li - Jefferies Samuel Durno - BTIG Harrison Parsons - Stephens Inc. Tom Stephan - Stifel David Saxon - Needham Jim Sidoti - Sidoti & Company Steve Lichtman - Oppenheimer Bruce Jackson - The Benchmark Company Operator Good day ladies and gentlemen. Thank you for standing by.

STAAR Surgical Company (STAA) Q2 2023 Earnings Call Transcript

Staar Surgical (STAA) came out with quarterly earnings of $0.40 per share, beating the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.42 per share a year ago.

Staar Surgical (STAA) Q2 Earnings Beat Estimates

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today reported financial results for the second quarter ended June 30, 2023. Second Quarter 2023 Overview Net Sales of $92.3 Million Up 14% includes a $0.7 Million sales reduction related to Other Products Record ICL Sales of $93.1 Million Up 19% Y/Y and Up 20% Y/Y in Constant Currency ICL Units Up 21% Y/Y Gross Margin at 76.6% vs. 78.8%.

STAAR Surgical Reports Second Quarter 2023 Results

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced that it will release financial results for the second quarter ended June 30, 2023 on Wednesday, August 2, 2023 after the market close. STAAR will host a conference call and webcast on Wednesday, August 2 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress. To access the confer.

STAAR Surgical to Report Second Quarter Results on August 2, 2023

Belite Bio Inc

Clearpoint Neuro Inc

Cooper Companies

iRhythm Technologies

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks That Are Set To Fly In Q2

STAAR Surgical is on the cusp of an acceleration in earnings and growth courtesy of its entrance into the US market. It is profitable, generates positive cash flow, and has zero real debt.

News for STAAR Surgical Stock (STAA)